drugset / Trial / NCT00617461

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461

Phase 2 Completed 96 enrolled XenoPort, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.

Timeline

Start
2008-03
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule 1200 mg Oral
Subject gabapentin enacarbil Small molecule 3600 mg Oral